Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The following is the supplementary data related to this arti
2020-07-06

The following is the supplementary data related to this article. Funding This work was supported by departmental funding to Prof. Mühl. Funding derived from the State of Hessia to the Institute of General Pharmacology and Toxicology at the pharmazentrum frankfurt (Head: Prof. Josef Pfeilschifter
-
rta 3 mg We performed three baseline scans in two baboons an
2020-07-06

We performed three baseline scans in two baboons and one blocking study by administering 1 mg/kg (i.v) meloxicam 30 min prior to [C]TMI injection (injected activity 175.75 ± 18.5 MBq, mass of unlabeled TMI rta 3 mg barrier (BBB) and retained in brain with a somewhat heterogeneous pattern (). Time ac
-
To respond to the need for QNAT
2020-07-06

To respond to the need for QNAT, commercial assays have been developed on automated systems. The first reagents for CMV and EBV VLs in whole blood were Abbott RealTime kits on the m2000 SP/RT system (Abbott Molecular Inc, Des plaines, USA) (M2000) [4,5] and Artus QS-RGQ kits on the QIAsymphony RGQ s
-
Acknowledgments The authors thank Dr
2020-07-06

Acknowledgments The authors thank Dr. Vladimir Poltoratsky and Zhihui Xiao for their help with the in vitro FRET assay. Support for this research was provided by Saint John’s University. Introduction We predicted the existence of endothelium-derived contractile factors (EDCFs) in 1982 [1]. In 1
-
br Dienogest DNG Dienogest is a
2020-07-06

Dienogest (DNG) Dienogest is a 19-nortestosterone derivative with two special structural changes [Fig. 1a]: [a] At the cabon-17 position there is a cyanomethyl group instead of an ethinyl group; [b] A double bond is present between carbons 9 and 10. DNG is the only progestogen that combines prope
-
Raloxifene is a second generation SERM that has tissue
2020-07-06

Raloxifene is a second generation SERM that has tissue-specific effects that differ from those of tamoxifen. Raloxifene was marketed for prevention and treatment of osteoporosis in postmenopausal women in the US and Europe. In a phase II randomized double-blind study, tamoxifen and raloxifene were e
-
PI K Akt signaling pathway
2020-07-06

PI3K/Akt signaling pathway is known in modulating cell apoptotic process (Saurus et al., 2015). To study the contribution of PI3K/Akt signaling pathway in ERRγ-mediated anti-apoptotic effect in podocytes, we examined phosphorylation of Akt and expression of PI3K subunits p110α and p85α via qRT-PCR a
-
DDR expression is upregulated in the
2020-07-03

DDR1 expression is upregulated in the glomeruli and tubules of injured kidneys [7], [8], [19]; however, what role this receptor plays in kidney resident Azithromycin is unclear. A plausible hypothesis is that DDR1 might contribute to kidney injury by directly exerting a pro-fibrotic action. In favo
-
bio bio We did not observe inhibition of vCPH
2020-07-03

We did not observe inhibition of vCPH by any of the TCA cycle intermediates (apart from the metal chelators citrate and isocitrate), nor by the factor inhibiting HIF (FIH; a 2OG-dependent asparaginyl hydroxylase) inhibitor N-oxalyl d-phenylalanine (NOF) or the γ-butyrobetaine dioxygenase inhibitor m
-
In our previous research we have focused
2020-07-03

In our previous research, we have focused on the discovery of novel VEGFR-2 inhibitors as anti-angiogenesis agents. Numbers of biphenyl-aryl urea incorporated with salicylaldoxime including BPS-7 have been developed as potent and selective VEGFR-2 inhibitors (Fig. 3) [12], [13], [14], [15], [16], [1
-
Conessine receptor Crystallographic and NMR based analyses h
2020-07-03

Crystallographic and NMR-based analyses have revealed that RINGs and U-boxes have a common mode of interaction with E2s (Fig. 2A). The key structural elements are two loop-like regions, which, in the case of RINGs, coordinate Zn. The loops surround a shallow groove formed by the central α-helix. Tog
-
Adrucil br Acknowledgments br Introduction Cysteinyl leukotr
2020-07-03

Acknowledgments Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic Adrucil and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pranlukast [3],
-
br P Y receptor structure br Pharmacology Several subtype
2020-07-03

P2Y receptor structure Pharmacology Several subtype selective compounds have been developed in recent years (Jacobson and Müller, 2016; Rafehi and Müller, 2018). These compounds are helpful tools for analyzing the roles of P2Y receptor subtypes in physiology and pathophysiology. The present ar
-
br Results and discussion br Conclusion In
2020-07-03

Results and discussion Conclusion In this research, several anti-inflammatory agents with pyrazolo[3,4-d]pyrimidine cores were synthesized. Such choice of large core than regular pyrazole was valid as a proper modification. That most of the prepared compounds showed excellent AI activity. In a
-
MAPKs are a family of phosphorylating enzymes that
2020-07-03

MAPKs are a family of phosphorylating enzymes that orchestrate various cellular response in proliferation, apoptosis, inflammation, stress response, and energy metabolism [11]. There are at least four major members including extracellular signal-regulated kinase 1 and 2 (ERK1/2), p38 mitogen-activat
16071 records 841/1072 page Previous Next First page 上5页 841842843844845 下5页 Last page